Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Part of paid clinical trials in Columbia, Missouri.

Sponsor
Corcept Therapeutics
Study ID
NCT06947304
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Nonalcoholic Steatohepatitis (NASH)

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Miricorilant — DRUG
    100 mg administered orally, once daily

Study Details

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Key Dates

Start date
Aug 22, 2025
Status verified
Feb 2026
Primary completion
May 31, 2026
Completion
May 31, 2026

Study Design

Enrollment
8 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Miricorilant- 100 mg
    Patients who meet the entry criteria for study CORT118335-858 will be enrolled to receive 100 mg of miricorilant every day for 6 weeks.

Primary Outcome Measure

Change in fasting hepatic lipogenesis after 6 weeks of treatment [ Time Frame: Baseline to Week 6 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of MissouriColumbiaMissouri65211
Elizabeth Parks, PhD
[email protected]
573-882-5864
Jessica George, BS
[email protected]
(573) 884-2014

Find similar trials in Columbia, MO

By research site
University of Missouri· Columbia, MO

Related Studies